Chinetti-Gbaguidi Giulia, Fruchart Jean-Charles, Staels Bart
UR 545 INSERM, Institut Pasteur de Lille, 1, rue Calmette BP245, 59019 Lille, France.
Curr Opin Pharmacol. 2005 Apr;5(2):177-83. doi: 10.1016/j.coph.2004.11.004.
Several conditions and risk factors predispose to cardiovascular disease, including visceral obesity, type 2 diabetes, insulin resistance, hypertension and dyslipidemia, and are collectively called the metabolic syndrome. Different pharmacological approaches are under development to address these risk factors and improve the cardiovascular risk profile. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that control lipid and glucose metabolism, as well as the inflammatory response. Thus PPARs appear good drug targets for the correction of the global risk profile that predisposes an individual to cardiovascular disease.
几种情况和风险因素易引发心血管疾病，包括内脏肥胖、2型糖尿病、胰岛素抵抗、高血压和血脂异常，这些因素统称为代谢综合征。目前正在研发不同的药理学方法来应对这些风险因素并改善心血管风险状况。过氧化物酶体增殖物激活受体（PPARs）是受配体激活的转录因子，可控制脂质和葡萄糖代谢以及炎症反应。因此，PPARs似乎是纠正使个体易患心血管疾病的整体风险状况的良好药物靶点。
